Compare AUB & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUB | COGT |
|---|---|---|
| Founded | 1902 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.6B |
| IPO Year | 2005 | 2018 |
| Metric | AUB | COGT |
|---|---|---|
| Price | $42.56 | $37.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | ★ $41.88 | $36.21 |
| AVG Volume (30 Days) | 941.1K | ★ 1.8M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.95 | N/A |
| Revenue | N/A | ★ $7,871,000.00 |
| Revenue This Year | $29.16 | N/A |
| Revenue Next Year | $4.59 | $1,733.58 |
| P/E Ratio | $21.99 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.87 | $11.53 |
| 52 Week High | $43.62 | $43.73 |
| Indicator | AUB | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 55.06 | 44.22 |
| Support Level | $40.74 | $36.53 |
| Resistance Level | $43.58 | $40.67 |
| Average True Range (ATR) | 0.71 | 1.99 |
| MACD | -0.07 | -0.54 |
| Stochastic Oscillator | 70.01 | 17.60 |
Atlantic Union Bankshares Corp is a financial and bank holding company based in the U.S. Through its community bank subsidiary and non-bank financial services affiliates, the company provides financial services, including banking, trust, and wealth management. It offers consumers and businesses a wide range of banking and related financial services, including checking, savings, certificates of deposit, and other depository services, as well as loans for commercial, industrial, residential mortgage, and consumer purposes. The company operates through two reportable operating segments: Wholesale Banking and Consumer Banking, with corporate support functions such as corporate treasury and others included in Corporate Other. It derives maximum revenue from the Wholesale Banking segment.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.